These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 17925661

  • 21. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M, Cecoli F, Fazzuoli L, De Franchis V, Ceresola E, Ferone D, Mussap M, Minuto F.
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
    Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P, Pietschmann P.
    Eur J Clin Invest; 2006 Aug; 36(8):566-73. PubMed ID: 16893379
    [Abstract] [Full Text] [Related]

  • 24. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M, Owczarska K, Sokołowska U, Centkowski P, Pogłód R, Kruk B.
    Arch Immunol Ther Exp (Warsz); 2005 Aug; 53(5):454-64. PubMed ID: 16314829
    [Abstract] [Full Text] [Related]

  • 25. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G, Carella C.
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [Abstract] [Full Text] [Related]

  • 26. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
    Mangiafico RA, Malaponte G, Pennisi P, Li Volti G, Trovato G, Mangiafico M, Bevelacqua Y, Mazza F, Fiore CE.
    J Intern Med; 2007 Jun; 261(6):587-96. PubMed ID: 17547714
    [Abstract] [Full Text] [Related]

  • 27. The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women.
    Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW.
    Am J Obstet Gynecol; 2005 Apr; 192(4):1087-93. PubMed ID: 15846185
    [Abstract] [Full Text] [Related]

  • 28. Association of the calcitonin gene (CA) polymorphism with bone mass and bone responsiveness to hormone therapy in postmenopausal Korean women.
    Kim JG, Choi YM, Moon SY, Lee JY.
    Menopause; 2003 Apr; 10(6):544-9. PubMed ID: 14627864
    [Abstract] [Full Text] [Related]

  • 29. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
    Ozkaya O, Buyan N, Bideci A, Gonen S, Ortac E, Fidan K, Cinaz P, Söylemezoğlu O.
    Nephron Clin Pract; 2007 Apr; 105(4):c153-8. PubMed ID: 17259742
    [Abstract] [Full Text] [Related]

  • 30. Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women.
    Dai Y, Shen L.
    Chin Med J (Engl); 2007 Nov 20; 120(22):2017-21. PubMed ID: 18067789
    [Abstract] [Full Text] [Related]

  • 31. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA, Mohamed NA, El-Metwally TH, Kamal MM.
    J Pediatr Hematol Oncol; 2010 May 20; 32(4):267-73. PubMed ID: 20445416
    [Abstract] [Full Text] [Related]

  • 32. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A, Navasa M, Peris P, Alvarez L, Pons F, Rodés J, Guañabens N.
    Liver Int; 2007 May 20; 27(4):492-7. PubMed ID: 17403189
    [Abstract] [Full Text] [Related]

  • 33. Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women.
    Prezelj J, Ostanek B, Logar DB, Marc J, Hawa G, Kocjan T.
    Menopause; 2008 May 20; 15(2):369-73. PubMed ID: 17882010
    [Abstract] [Full Text] [Related]

  • 34. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
    Pulsatelli L, Dolzani P, Silvestri T, Caraceni P, Facchini A, Ravaglia G, Salvarani C, Melicòni R, Mariani E.
    Biogerontology; 2004 May 20; 5(2):119-27. PubMed ID: 15105586
    [Abstract] [Full Text] [Related]

  • 35. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
    Ostrowska Z, Świętochowska E, Marek B, Kajdaniuk D, Tyrpień-Golder K, Wołkowska-Pokrywa K, Damasiewicz-Bodzek A, Kos-Kudła B.
    Endokrynol Pol; 2014 May 20; 65(6):438-48. PubMed ID: 25554611
    [Abstract] [Full Text] [Related]

  • 36. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Szapska B, Wołkowska-Pokrywa K, Dyduch A.
    Bone; 2012 Jan 20; 50(1):156-60. PubMed ID: 22001124
    [Abstract] [Full Text] [Related]

  • 37. The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL.
    Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Grapsa EI, Passalidou IA, Tziamalis MP, Poulakou MV, Vlachos IS, Perrea DN.
    Hemodial Int; 2008 Jan 20; 12(1):100-7. PubMed ID: 18271850
    [Abstract] [Full Text] [Related]

  • 38. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis.
    Jiang LS, Zhang ZM, Jiang SD, Chen WH, Dai LY.
    J Bone Miner Res; 2008 Apr 20; 23(4):475-83. PubMed ID: 18052758
    [Abstract] [Full Text] [Related]

  • 39. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
    Crisafulli A, Altavilla D, Squadrito G, Romeo A, Adamo EB, Marini R, Inferrera MA, Marini H, Bitto A, D'Anna R, Corrado F, Bartolone S, Frisina N, Squadrito F.
    J Clin Endocrinol Metab; 2004 Jan 20; 89(1):188-92. PubMed ID: 14715848
    [Abstract] [Full Text] [Related]

  • 40. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C.
    Bone; 2004 Sep 20; 35(3):785-91. PubMed ID: 15336617
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.